Loading patent…
AssigneeValorisation Recherche Hscm, Limited Partnership
InventorsKarim Maghni, Nadia Ouaked, Bertrand Lefort, Sandra Favret
Estimating the term…
The present invention relates to neurokinin-1 (NK-1) receptor antagonists in combination with an inhibitor of metachromatic cell activation, such as an anti-inflammatory agent, an immunosuppressor, or a kinase inhibitor, and use of such combinations in the treatment of disorders associated with activation of metachromatic cells. Disorders associated with the activation of metachromatic cells include allergic/non-allergic rhinitis, allergic/non-allergic asthma, allergic/non-allergic urticaria, immuno-inflammatory disorders, metachromatic cell-related autoimmune disorders, transplant rejection, and other metachromatic cell-related disorders.
-123. (canceled)
A composition comprising an NK-1 receptor inhibitor and an anti-inflammatory compound, wherein the NK-1 receptor inhibitor is not a compound encompassed by Formula I, Aprepitant, or Casopitant/GW679769 ((2R,4S)-4-(4-acetylpiperazin-1-yl)-N-{(1R)-1-[3,5-bis(trifluoromethyl)=phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide).
A composition comprising (i) an NK-1 receptor inhibitor, (ii) an inhibitor of metachromatic cell activation, and (iii) a beta-2 adrenergic receptor agonist.
A method of treating a disease, disorder, or condition associated with metachromatic cell activation in a subject, said method comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an NK-1 receptor inhibitor and an inhibitor of metachromatic cell activation, wherein the NK-1 receptor inhibitor is not a compound encompassed by Formula I, or Casopitant/GW679769 ((2R,4S)-4-(4-acetylpiperazin-1-yl)-N-{(1R)-1-[3,5-bis(trifluoromethyl)=phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide).
A method of treating a disorder selected from the group consisting of allergic or non-allergic rhinitis, allergic or non-allergic asthma, allergic or non-allergic urticaria, an immuno-inflammatory disorder, an autoimmune disorder, and transplant rejection in a subject, said method comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an NK-1 receptor inhibitor and an inhibitor of metachromatic cell activation, wherein the NK-1 receptor inhibitor is not a compound encompassed by Formula I.
Dependencies are inferred from the claim text.